Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 umbrella trial of MK-5909, MK-2400, and docetaxel in previously treated stage IV squamous NSCLC
MOH_2025-02-16_013829Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of raludotatug deruxtecan, ifinatamab deruxtecan and docetaxel in Pulmonary squamous cell carcinoma (4 arms), sponsored by Merck & Co. Started Feb 2025; status: recruiting.
02
Drugs
raludotatug deruxtecanifinatamab deruxtecandocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on MOH_2025-02-16_013829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013829.